Chaman Lal Setia Exports Limited Buyback 2024
1. Business Model:
Export-Oriented: Chaman Lal Setia Exports Limited (CLSEL) primarily operates as an export-oriented company. It focuses on exporting premium quality Basmati rice to international markets, leveraging India’s reputation for high-quality rice.
2. Products and Services:
a) Basmati Rice Varieties: The company specializes in various types of Basmati rice, including Traditional Basmati, Pusa Basmati, 1121 Basmati, and other premium variants.
b) Rice-Related Products: CLSEL also offers rice-related products such as rice bran oil and other value-added products, catering to diverse consumer needs.
3. Branches and Global Reach:
CLSEL has a significant global presence, exporting to over 80 countries across North America, Europe, the Middle East, and Asia. The company operates multiple processing units and warehouses strategically located in key rice-producing regions to ensure efficient logistics and supply chain management.
4. Achievements:
The company is one of the leading exporters of Basmati rice from India, known for its commitment to quality and customer satisfaction. CLSEL has received numerous accolades for its export performance and product quality. It has been recognized by various industry bodies and export promotion councils.
5. Market Leadership:
CLSEL employs state-of-the-art processing and packaging facilities to maintain the highest standards of quality and hygiene. The company holds several international quality certifications, ensuring its products meet global standards and consumer expectations.
Buy Back Offer Deal:
Buyback Type: | Tender Offer |
Buyback Record Date: | Aug 19 2024 |
Buyback Opening Date: | Aug 23 2024 |
Buyback Closing Date: | Aug 29 2024 |
Buyback Offer Amount: | ₹ 60.23 Cr. |
Date of Board Meeting approving the proposal: | Aug 06 2024 |
Date of Public Announcement: | Aug 06 2024 |
Buyback Offer Size: | 3.88% |
Buyback Number of Shares: | 20,07,930 |
FV: | 2 |
Buyback Price: | ₹ 300 Per Equity Share |
Details of Buyback:
Salient financial parameters:
Particulars (In Cr)
|
Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
Sales + | 798 | 851 | 932 | 1,387 | 1,356 |
Expenses + | 719 | 734 | 837 | 1,228 | 1,194 |
Operating Profit | 79 | 118 | 95 | 159 | 162 |
OPM % | 10% | 14% | 10% | 11% | 12% |
Other Income + | 3 | 3 | 4 | 11 | 10 |
Interest | 7 | 6 | 7 | 7 | 10 |
Depreciation | 5 | 5 | 5 | 6 | 7 |
Profit before tax | 70 | 110 | 87 | 157 | 155 |
Tax % | 25% | 25% | 25% | 25% | 25% |
Net Profit + | 52 | 82 | 65 | 118 | 116 |
EPS in Rs | 10.14 | 15.85 | 12.56 | 22.75 | 22.35 |
Dividend Payout %
|
5% | 4% | 0% | 4% | 10% |
How to Participate in buyback?
Profit from the buyback on the bases of acceptance Ratio:
Acceptance Ratio | 33% | 50% | 75% | 100% |
Amount Invested in Buyback | 148518 | 148518 | 148518 | 148518 |
No. of Shares Buyback | 220 | 333 | 500 | 666 |
Buyback Profit | 16940 | 25641 | 38500 | 51282 |
Profit% | 11.41% | 17.26% | 25.92% | 34.53% |
7 Comments
Leave a Reply
You must be logged in to post a comment.
AR is 160/585. Not bad.
Received mail ? Or broker sms or contract?
Received mail.
E R only 50 for 600. Atleast CMP is above my purchase price .
Gopi sir is it okay to participate in this opportunity ?
With a size of 3.88percet this one looks good to see. Aurobindo Pharma crossed buyback price today.Quality also matters a lot.
I have already bought 600@241/Now it is over 251/. Please take your own decision.